非布司他多少钱？

(Febuxostat) is a drug used to treat gout caused by high uric acid levels. It is usually only recommended for patients who cannot take allopurinol. This product is not recommended for the treatment of asymptomatic hyperuricemia. How much does febuxostat cost?

The price of the original febrestat drug produced in Japan is higher than that in India, about $1,500 per box. Febuxostat produced by Zydus Pharmaceuticals in India has the same efficacy as the original drug, but the price is much lower. The specification is 80mg*30 tablets/box, and its price is about $200. Everyone should choose drugs according to their actual needs.

The recommended starting dose of febuxostat tablets is 40 mg. Once a day. If after 2 weeks. The blood uric acid level is still not less than 6 mg/dl (about 360 μmol/L). It is recommended that the dose be increased to 80mg. Once a day. When administering medication. There is no need to consider the effects of food and antacids. For special groups of people, the method and dosage may be different:

1. Renal insufficiency

No dose adjustment is required in patients with mild to moderate renal impairment. The recommended starting dose of this product is 40 mg once daily. For patients whose sUA value is still higher than 6 mg/dLd after two weeks of 40 mg medication, the recommended dosage is 80 mg. There is no sufficient research data on the use of this product in patients with severe renal insufficiency. Such patients should be cautious when taking this product.

2. Medication for children

There are no pharmacokinetic studies on the use of this product in patients under 18 years of age.

3. Medication for elderly patients

After multiple doses of oral administration of this product to elderly patients (≥65 years old), the Cmax and AUC of febuzoxostat and its metabolites were similar to those in younger patients (18-40 years old). In addition, the percentage decrease in serum uric acid concentration was similar in older and younger subjects. No dose adjustment is required for elderly patients.

4. Liver damage

Following multiple oral doses of 80 mg in patients with mild (cirrhosis grade A) and moderate (cirrhosis grade B) liver impairment, Cmax and AUC24 (total and unbound) increased by 20-30% compared with subjects with normal liver function. The percentage reduction in serum uric acid concentration was similar between different groups (62% in healthy subjects, 49% in the mild liver impairment group, and 48% in the moderate liver impairment group). Studies in patients with severe (cirrhosis class C) liver impairment have not been conducted and should be used with caution in these patients.